Axsome Therapeutics Inc (NASDAQ:AXSM) CFO Nick Pizzie bought 1,920 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were acquired at an average cost of $20.80 per share, for a total transaction of $39,936.00. Following the completion of the purchase, the chief financial officer now owns 1,920 shares in the company, valued at $39,936. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Nick Pizzie also recently made the following trade(s):
- On Tuesday, March 19th, Nick Pizzie bought 5,400 shares of Axsome Therapeutics stock. The shares were acquired at an average cost of $12.58 per share, for a total transaction of $67,932.00.
Shares of NASDAQ:AXSM traded up $0.90 during trading hours on Thursday, reaching $23.02. The stock had a trading volume of 599,354 shares, compared to its average volume of 1,270,137. Axsome Therapeutics Inc has a 1 year low of $1.94 and a 1 year high of $26.45. The company has a current ratio of 5.68, a quick ratio of 5.68 and a debt-to-equity ratio of 1.08. The company has a market cap of $736.82 million, a PE ratio of -20.02 and a beta of 2.78.
Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.01). As a group, equities research analysts expect that Axsome Therapeutics Inc will post -1.29 EPS for the current year.
Several large investors have recently made changes to their positions in AXSM. Barclays PLC purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $30,000. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Axsome Therapeutics by 113.7% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,400 shares of the company’s stock valued at $48,000 after purchasing an additional 1,809 shares during the last quarter. Focused Wealth Management Inc purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at approximately $64,000. Bank of New York Mellon Corp purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $98,000. Finally, Weiss Asset Management LP purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at approximately $171,000. 44.22% of the stock is currently owned by institutional investors.
Several equities research analysts recently weighed in on AXSM shares. BidaskClub downgraded shares of Axsome Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, March 3rd. HC Wainwright set a $15.00 target price on shares of Axsome Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Cantor Fitzgerald upped their target price on shares of Axsome Therapeutics from $13.00 to $16.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 20th. Finally, BTIG Research upped their target price on shares of Axsome Therapeutics to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $30.83.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.